aTyr Pharma Stock Discussion

$aTyr Pharma (ATYR.US)$
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

$aTyr Pharma (ATYR.US)$
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compar...

$aTyr Pharma (ATYR.US)$ prolly gonna get shorted heavily today